Paliperidone Biogaran

Paliperidone, the active ingredient in Paliperidone Biogaran, is an atypical antipsychotic presented as a strength/form for oral use. It treats schizophrenia and schizoaffective disorder in adults. GNH USA supplies Paliperidone Biogaran as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Paliperidone Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychotic disorders. - Schizophrenia: Reduces positive and negative symptoms and helps maintain stability. - Schizoaffective disorder: Improves mood and psychotic symptom control. - Maintenance therapy: Prevents relapse in patients with established psychotic illness.

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Headache - Insomnia - Restlessness (akathisia) - Weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Seizures - Significant orthostatic hypotension - Hyperglycaemia - Elevated prolactin levels with associated endocrine effects

Before initiating therapy with Paliperidone, clinicians should evaluate patient history and monitor for specific safety concerns. - Cardiovascular assessment: Check for QT‑prolongation risk and baseline ECG. - Metabolic monitoring: Track weight, glucose and lipid levels regularly. - Movement disorders: Observe for early signs of extrapyramidal symptoms. - Pregnancy and lactation: Use only if benefits outweigh risks. - Renal function: Adjust if severe impairment is present. - Store at ambient temperature: keep in original container, protect from moisture and light.

Paliperidone can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin) – may reduce effectiveness. - Other dopamine antagonists – heightened risk of extrapyramidal symptoms.

Moderate Interactions (Monitor Closely): - Antihypertensives – may enhance orthostatic hypotension. - CNS depressants (e.g., benzodiazepines) – additive sedation. - Anticholinergic agents – may worsen constipation and dry mouth.